Companies › BriaCell Therapeutics
3 active drug programs in 29 registered trials: 15 Phase 2, 10 Phase 1, 4 Phase 3; Oncology; next expected readout Dec 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Interferon Alfa-2B Interferon alpha/beta receptor agonist | IFNAR1, IFNAR2 | Phase 3 | Breast Cancer; Colorectal Neuroendocrine Tumor G1; Prostate Adenocarcinoma; Polycythemia Vera | Dec 2027 |
| Retifanlimab Programmed cell death protein 1 antagonist | PDCD1 | Phase 3 | Breast Cancer; Anatomic Stage IV Breast Cancer AJCC v8; Merkel Cell Carcinoma; Recurrent Glioblastoma … | Dec 2027 |
| SV-BR-1-GM Allogeneic whole cell breast tumor cell line transfected with CSF2 gene encoding GM-CSF; p | CSF2 | Phase 3 | Breast Cancer | Dec 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04445844 | Retifanlimab | Phase 2 | Anatomic Stage IV Breast Cancer AJCC v8 | Oncology | Jun 2025 |
| NCT05594290 | Retifanlimab | Phase 2 | Merkel Cell Carcinoma | Oncology | Nov 2026 |
| NCT06160206 | Retifanlimab | Phase 2 | Recurrent Glioblastoma | Oncology | Nov 2026 |
| NCT04494009 | Retifanlimab | Phase 2 | Esophageal Cancer | Oncology | Dec 2026 |
| NCT05455697 | Retifanlimab | Phase 1 | Diffuse Large B-Cell Lymphoma | Oncology | Jan 2027 |
| NCT06056895 | Retifanlimab | Phase 2 | Unresectable Clinical Stage III Merkel Cell Carcinoma AJCC v8 | Oncology | Jan 2027 |
| NCT00569127 | Interferon Alfa-2B | Phase 3 | Colorectal Neuroendocrine Tumor G1 | Oncology | Jan 2027 |
| NCT06320405 | Retifanlimab | Phase 1 | Advanced Malignant Solid Neoplasm | Oncology | Apr 2027 |
| NCT03899987 | Interferon Alfa-2B | Phase 2 | Prostate Adenocarcinoma | Oncology | Apr 2027 |
| NCT05345002 | Retifanlimab | Phase 2 | Glioma | Oncology | Jun 2027 |
| NCT04438824 | Retifanlimab | Phase 2 | Well-differentiated/Dedifferentiated Liposarcoma | Oncology | Jun 2027 |
| NCT04577014 | Retifanlimab | Phase 1 | Soft Tissue Sarcoma | Oncology | Sep 2027 |
| NCT06149481 | Retifanlimab | Phase 1 | Metastatic Colorectal Cancer | Oncology | Oct 2027 |
| NCT06072612 | SV-BR-1-GM | Phase 3 | Breast Cancer | Oncology | Dec 2027 |
| NCT06072612 | Retifanlimab | Phase 3 | Breast Cancer | Oncology | Dec 2027 |
| NCT07219576 | Retifanlimab | Phase 1 | Non Small Cell Lung Carcinoma | Oncology | Dec 2027 |
| NCT06072612 | Interferon Alfa-2B | Phase 3 | Breast Cancer | Oncology | Dec 2027 |
| NCT06389799 | Retifanlimab | Phase 2 | Dedifferentiated Liposarcoma | Oncology | Dec 2027 |
| NCT04470024 | Retifanlimab | Phase 1 | Cancer of the Head and Neck | Oncology | Dec 2027 |
| NCT05083754 | Retifanlimab | Phase 1 | Glioblastoma Multiforme | Oncology | Jan 2028 |
| NCT06896188 | Retifanlimab | Phase 1 | Pancreatic Adenocarcinoma | Oncology | Mar 2028 |
| NCT05870475 | Interferon Alfa-2B | Phase 2 | Polycythemia Vera | Oncology | Mar 2028 |
| NCT04968106 | Retifanlimab | Phase 2 | Resectable Sarcoma | Oncology | Apr 2028 |
| NCT07425054 | Retifanlimab | Phase 2 | Anal Cancer | Oncology | Jan 2029 |
| NCT05743595 | Retifanlimab | Phase 1 | Unmethylated Glioblastoma | Oncology | Mar 2029 |
| NCT04225039 | Retifanlimab | Phase 2 | Glioblastoma | Oncology | Apr 2029 |
| NCT05177133 | Retifanlimab | Phase 2 | Gastric Adenocarcinoma | Oncology | Nov 2029 |
| NCT04374305 | Retifanlimab | Phase 2 | Neurofibromatosis Type 2 | Oncology | Dec 2029 |
| NCT07468136 | Retifanlimab | Phase 1 | Anaplastic Oligodendroglioma | Oncology | Oct 2030 |
Cash and short-term investments of $21m on 2026-07-31; operating cash outflow about $29m a year; runway about 9 months at that burn, to Apr 2027; 5 of 6 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Genelux Imunon Actuate Therapeutics Actinium Pharmaceuticals pharmaand
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.